Opioid Avoidance In Surgery Through Integrating Suzetrigine: Post-Operative Care Phase Pilot

NCT07257133 Phase 4 COMPLETED

This prospective, single-arm feasibility study will evaluate postoperative pain control, opioid use, and early recovery outcomes in adult patients undergoing elective outpatient facial plastic surgery who receive suzetrigine as part of their standard postoperative analgesic regimen.

Details

Lead sponsor	Mayo Clinic
Phase	Phase 4
Status	COMPLETED
Enrolment	100
Start date	2025-10-20
Completion	2026-04-01

Conditions

• Post Operative Pain

Interventions

• Suzetrigine

Primary outcomes

• Total opioid consumption — 7 days post-operation
  Number of opioid pills used during the first 7 postoperative days
• Number of patients with no rescue use — 7 days post-operation
  Total number of patients who do not use any rescue opioids postoperatively

Countries

United States